Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Hepatol ; 33(3): 469-75, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11020004

RESUMO

BACKGROUND/AIMS: Hepatitis B mutant strains of virus emerging during treatment with the nucleoside analog lamivudine are being increasingly recognized. In the majority of lamivudine-resistant isolates the mutations have been reported to occur within the YMDD motif of the viral polymerase, either as a single mutation M552I or as M552V concomitant with L528M. We analyzed the time course and genetic succession pattern during the emergence of lamivudine resistance. METHODS: Seven patients with breakthrough viremia in the setting of chronic hepatitis (n=5) or recurrent HBV after liver transplantation (n=2) were investigated. Pre- and post-breakthrough serum samples were evaluated by single- or second-round PCR amplification and sequencing analysis. RESULTS: Genotypic succession of the virus populations was observed to occur from M552I to M552I/L528M (n=2) and from L528M to M552V/L528M (n=1). The double mutations M552I/L528M (n=4) or M552V/L528M (n=2) were found in six out of seven patients, and represented the stable virus populations throughout the follow-up period. Breakthrough viremia was not associated with the single L528M mutation. The mean duration of uninterrupted treatment with lamivudine until breakthrough was 422 days (range 182-642) and was longer in the setting of chronic hepatitis B than in recurrent hepatitis B after liver transplantation. HBV DNA levels after breakthrough were lower than pretreatment levels in the majority of patients with chronic hepatitis but higher after liver transplantation. CONCLUSION: Our observations show that the virus populations conferring resistance to lamivudine can evolve from single to double mutations at amino acid 552 and 528 of the HBV polymerase, and that M552I/ L528M or M552V/L528M seem to be the predominant mutations arising during long-term antiviral therapy with lamivudine.


Assuntos
Antivirais/uso terapêutico , DNA Polimerase Dirigida por DNA/genética , Vírus da Hepatite B/enzimologia , Hepatite B/tratamento farmacológico , Lamivudina/uso terapêutico , Mutação/genética , Adulto , Sequência de Bases/genética , DNA Viral/sangue , Resistência Microbiana a Medicamentos/genética , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Transaminases/sangue
2.
Int J Pediatr Nephrol ; 8(2): 91-4, 1987.
Artigo em Inglês | MEDLINE | ID: mdl-3654064

RESUMO

The role of urologic disease and manipulation of the genito-urinary tract in the pathogenesis of gram-negative bacteremia has been long recognized. Among these organisms, species of providencia genus have been increasingly reported. We describe a 17-year-old male paraplegic who developed septic shock due to Providencia Stuartii following urinary tract manipulation and responding to medical therapy. This is unusual as most cases with septic shock from providencia species will succumb. It is important to review this case since providencia species appear to be increasingly common in paraplegic patients.


Assuntos
Infecções por Proteus , Sepse/etiologia , Adolescente , Quimioterapia Combinada , Humanos , Canamicina/administração & dosagem , Masculino , Paraplegia/complicações , Infecções por Proteus/tratamento farmacológico , Providencia , Sepse/tratamento farmacológico , Choque Séptico/tratamento farmacológico , Choque Séptico/etiologia , Ticarcilina/administração & dosagem , Bexiga Urinaria Neurogênica/complicações , Cateterismo Urinário/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA